Fineline Cube

Follow:
14421 Articles
Innovent's Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial
CompanyDrug

Innovent’s Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial

Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&D Programs
Company

Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&D Programs

Astellas Establishes First China Innovation R&D Center in Beijing BioPark
Company

Astellas Establishes First China Innovation R&D Center in Beijing BioPark

Novartis Transfers Lucentis and Beovu Rights to CMS Vision in China Deal
CompanyDeals

Novartis Transfers Lucentis and Beovu Rights to CMS Vision in China Deal

GSK Secures Global Rights to Syndivia’s ADC for Metastatic Prostate Cancer
CompanyDeals

GSK Secures Global Rights to Syndivia’s ADC for Metastatic Prostate Cancer

Zhifei's CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia
CompanyDrug

Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia

LEO Pharma Submits NDA for Anzupgo in China for Chronic Hand Eczema
CompanyDrug

LEO Pharma Submits NDA for Anzupgo in China for Chronic Hand Eczema

Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India
CompanyDeals

Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India

Alphamab Announces First Patient Dosed with JSKN022, a PD‑L1/αvβ6 Bispecific ADC
CompanyDrug

Alphamab Announces First Patient Dosed with JSKN022, a PD‑L1/αvβ6 Bispecific ADC

Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC
CompanyDrug

Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC

Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
CompanyDrug

Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

NMPA Expands Reference Listed Drugs List to 98 Items for Chemical Generic Drugs
Policy / Regulatory

NMPA Expands Reference Listed Drugs List to 98 Items for Chemical Generic Drugs